BofA raised the firm’s price target on Cardinal Health (CAH) to $216 from $180 and keeps a Buy rating on the shares following “strong” Q1 results. Overall, the quarter underscores BofA’s confidence in the go-forward trajectory of the core pharmaceutical business and achievability of Cardinal Health’s long-term 12%-14% adjusted EPS targets, the firm told investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAH:
- Early notable gainers among liquid option names on October 30th
- Morning Movers: Alphabet, Eli Lilly rise following quarterly results
- Cardinal Health Reports Strong Q1 2026 Revenue Growth
- Cardinal Health reports Q1 EPS $2.55, consensus $2.17
- Cardinal Health raises FY26 EPS view to $9.65-$9.85 from $9.30-$9.50